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cAccuracy of a Novel Risk Index Combining Degree of Stenosis of the
Carotid Artery and Plaque Surface Echogenicity
Momjiam-Mayor L, Kuzmanovic I, Momjiam S, et al. Stroke 2012;43:
1260-5.
Conclusion: A new ultrasound risk index parallels the presence of
symptoms and may be a means of assessing the clinical risk of a carotid
plaque.
Summary: Thus far, prophylactic intervention for carotid artery steno-
sis is determined primarily by the severity of the degree of the stenosis.
However, stenosis severity itself in asymptomatic patients is relatively insen-
sitive in determining which patients develop neurologic symptoms. Addi-
tional variables, such as plaque morphology, may also play an important role
in occurrence of cerebrovascular events and may be predictors of ipsilateral
stoke that act independently or in concert with the degree of stenosis. The
authors developed an ultrasound risk index (RI) based on the combination
of degree of stenosis and echogenicity of the plaque surface. In this study,
the aim was to evaluate the accuracy of the RI in a cohort of consecutive
patients presenting with symptomatic or asymptomatic carotid stenosis. In
addition, the authors wished to compare this method with other well-
established parameters, including degree of stenosis alone and gray-scale
median of the plaque, for predicting potential neurologic events associated
with carotid stenosis. The authors used consecutive patients with 50% to 99%
internal carotid stenosis. Semi-automated gray scale-based color mapping
(red, yellow, and green) of the whole plaque and of its surface was pre-
formed. The surface was defined as the region located between the lumen
(level 0) and, respectively, 0.5, 1, 1.5, and 2 mm below the surface. RI was
based on the combination of the degree of stenosis and the proportion of red
color (indicating low echogenicity) on the surface or in the whole plaque.
There were 67 symptomatic and 117 asymptomatic carotid stenoses ana-
lyzed. RI values were higher among symptomatic lesions (0.46 vs 0.29; P
.001). Using receiver operating characteristic curves, RI had stronger pre-
dictive value compared with degree of stenosis or surface echogenicity alone.
In a regression model that included age, gender, degree of stenosis, surface
echogenicity, gray-scale median of the whole plaque, and RI, RI measured
within the surface region (0.5 mm from the lumen) was the only parameter
significantly associated with the presence of symptoms (odds ratio, 4.89;
95% confidence interval, 2.7-8.7; P  .0000002). RI was also the best
criteria to differentiate between symptomatic and asymptomatic stenosis (RI
value 0.36, sensitivity 78% and specificity 65%).
Comment:These authors studiedmany different parameters to predict
symptoms associated with carotid plaque, including age, gender, degree of
stenosis, surface echogenicity, gray-scale median of the whole plaque, and
RI. Of all these parameters, it is intriguing that only RI measured within the
surface region located 0.5 mm from the lumen was significantly associated
with the presence of symptoms. Unfortunately, the authors’ RI, while an
intriguing new ultrasound parameter, appears somewhat difficult to calcu-
late, and it is unknown if the data are reproducible among different centers.
It is somewhat amazing that after 30 years, it is still only the degree of
stenosis of the internal carotid artery that is an accepted parameter for
prediction of stroke secondary to internal carotid artery stenosis.
Cardiovascular Benefits and Diabetes Risks of Statin Therapy in Pri-
mary Prevention: An Analysis From the JUPITER Trial
Ridker PM, Pradhan A, MacFadyen JG, et al. Lancet 2012;380:565-71
Conclusion: The cardiovascular mortality benefits of statin therapy
exceed the potential diabetes hazard induced by statins.
Summary: Recent trial data and meta-analysis have suggested that
statins confer an increase risk for development of diabetes (Ridker PM, et al,
N Engl J Med 2008;359:2195-207; and Sattar N, et al, Lancet 2010;375:
735-42). Recognition of the increased risk of diabetes with statin therapy has
lead to questions on the balance of benefit and risk of statin drugs for primary
prevention. The authors, therefore, analyzed data from participants from the
JUPITER trial to address the balance of vascular benefits and diabetes
hazards with statin use. In the JUPITER trial, 17,603 men and women
without previous cardiovascular disease were randomly assigned to rosuvas-
tatin (20 mg/d) or placebo and were monitored for 5 years for the primary
end point of myocardial infarction, stroke, admission to the hospital for
unstable angina, arterial revascularization, or cardiovascular death. Prespeci-
fied secondary end points of the trial included venous thromboembolism,
incident of physician-reported diabetes, and all-causemortality.With respect
to diabetes development, patients were stratified on the basis of having none
or at least one of the major four risk factors for developing diabetes: metabolic
syndrome, impaired fasting glucose, body mass index 30 kg/m2, or
M
mlycated hemoglobin A1c 6%. There were 11,508 trial participants with
ne or more major diabetes risk factors. In individuals with one or more
iabetes risk factors, statin allocation was associated with a 39% reduction in
he primary end point (hazard ratio [HR], 0.61, 95% confidence interval
CI], 0.47-0.79, P .0001), a 36% reduction in venous thromboembolism
HR, 0.64; 95% CI, 0.39-1.06; P .08), a 17% reduction in total mortality
HR, 0.83; 95% CI, 0.64-1.0; P .15), and a 28% increase in diabetes (HR,
.28; 95% CI, 1.07-1.54, P .01). For those with diabetes risk factors, 134
ascular events or deaths were avoided for every 54 new cases of diabetes
iagnosed. For trial participants with no major diabetes risk factors, statin
llocation was associated with a 52% reduction in the primary end point
HR, 0.48; 95% CI, 0.33-0.68; P  .001), a 53% reduction in venous
hromboembolism (HR, 0.47; 95% CI, 0.21-1.03; P  .05), a 22% reduc-
ion in total mortality (HR, 0.78l; 95% CI, 0.59-1.03; P  .08), and no
ncrease in diabetes (HR, 0.99; 95% CI, 0.45-2.21; P  .99). In patients
ithout diabetes risk factors, 86 vascular events were avoided, with no new
ases of diabetes diagnosed. In the 486 participants in the trial who devel-
ped diabetes in the follow-up (270 on rosuvastatin vs 216 on placebo; HR,
.25, 95% CI, 1.05-1.49; P .01), the point estimate of cardiovascular risk
eduction associated with statin therapy (HR, 0.63; 95% CI, 0.25-1.06) was
onsistent with that for the trial as a whole (HR, 0.56; 95% CI, 0.46-0.69).
ompared with placebo, statin accelerated the average time to diagnosis of
iabetes by 5.4 weeks (83.3 [standard deviation, 47.8] weeks on rosuvasta-
in vs 89.7 [50.4] weeks on placebo).
Comment: Three meta-analyses were published between 2009 and
011 indicating an increase risk of type 2 diabetes in patients taking a statin
edication. In addition, intensive-dose statin therapy appeared to be asso-
iated with higher risk than lower-dose therapy (Preiss D, et al, JAMA
011;305:2556-64). This prompted the Food and Drug Administration to
ecommend safety label changes to statin drugs (http://www.FDA.gov/
rugs/drugsaftey/ucm293101.htm). This report, while confirming the in-
reased risk of diabetes in patients on statin medications, suggests that in the
etting of primary prevention, even in the face of risk factors for development
f diabetes, the use of statin medications has a favorable overall effect on
ortality and cardiovascular events, despite an increased risk of diabetes.
he authors believe the data provide reassurance for patients and physicians
ith regard to lipid-lowering agents as adjuncts to smoking sensation,
xercise, and diet in the prevention of major cardiovascular events.
hanges in Abdominal Aortic Aneurysms Rupture and Short-Term
ortality, 1995-2008: A Retrospective Observational Study
chermerhorn ML, Bensley RP, Giles KA, et al. Ann Surg 2012;256:651-8.
Conclusion: Decreases in mortality from abdominal aortic aneurysm
AAA), both from rupture and short-term repair, are likely related to the
ntroduction and expansion of endovascular aneurysm repair (EVAR).
Summary: EVAR was approved by the U.S. Food and Drug Admin-
stration in 1999 and has resulted in lower perioperative mortality and
orbidity, as documented in three large randomized trials and in the U.S.
edicare population. Decreased morbidity and mortality associated with
VAR, combined with widespread use of abdominal imaging studies, has
esulted in more aneurysms being detected than in the past and more
neurysms being repaired. The authors’ hypothesis was that increased rates
f detection and elective repair of AAA, in combination with increasing use
f EVAR, should be associated with decreased short-term AAA-related
ortality. To test their hypothesis, they identified Medicare beneficiaries
ndergoing elective AAA repair and patients hospitalized with a ruptured
AA (rAAA) from 1995 to 2008. They then calculated standardized annual
ates of AAA-related deaths from elective repair or rupture. During the study
eriod, 338,278 patients underwent intact AAA repair, and there were
9,653 patients with rAAA, of whom 47,524 underwent repair. Repairs of
ntact AAAs increased substantially in those aged 80 years (57.7 to 92.3
er 100,000, P .001) but decreased in those aged 65 to 74 years (81.8 to
8.9, P  .001). By 2008, 77% of all intact repairs and 31% of all rAAA
epairs were performedwith EVAR (P .001). Operativemortality declined
or intact repair (4.9% to 2.4%, P  .001) and for rAAA repair (44.1% to
6.3%, P  .001). Short-term AAA-related deaths decreased by more than
alf (26.1 to 12.1 per 100,000, P  .001), with the greatest decline
ccurring in those aged 80 years (53.7 to 27.3, P  .001).
Comment: The results presented here parallel those presented earlier
his year in the British Journal of Surgery (Anjum A, et al. Br J Surg
012;99:637-45) documenting overall decreasing mortality from AAA. The
urrent study focused primarily on procedurally related deaths. Use of the
edicare database, however, cannot completely dissect all of the factors that
ay be related to a decrease in AAA mortality. For example, it is certainly
1809
